Funding for this research was provided by:
National Natural Science Foundation of China (81401877)
Program for young talents of Zhongshan Hospital, Fudan University (2015ZSYXQN18)
Natural Science Foundation of China (81770039, 81570028, 81490533, 81400018)
National Science and Technology major project"Key new drug creation and manufacturing program" (2018ZX092001002-006)
Zhongshan hospital clinical research foundation (2016ZSLC05, 2019ZSGG15)
Shanghai municipal key clinical specialty (shslczdzk02201)
Shanghai top-priority clinical key disciplines construction project (2017ZZ02013)
Received: 22 October 2019
Accepted: 17 March 2020
First Online: 30 March 2020
Ethics approval and consent to participate
: The human participants involved in this research provided their written informed consent, according to the principles expressed in the Declaration of Helsinki. The Medical Ethics and Human Clinical Trial Committee at Zhongshan Hospital of Fudan University approved this study as well as the consent procedure (Permit Number: 2011–221). All animal protocols were approved by the Ethical Committee on Animal Experiments of the University of Fudan Animal Care Committee, Shanghai, China. All animal experiments were carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986.
: The human participants involved in this research consent to publish the manuscript and all the authors agree with the submission and publication of this manuscript.
: The authors declare that they have no competing interests.